Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Investigational agent plus enfortumab vedotin and pembrolizumab for advanced urothelial carcinoma
NL-OMON60384Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of MK-3120, enfortumab vedotin and pembrolizumab, sponsored by Merck & Co. Started Mar 2026; status: recruiting.
02
Drugs
Beyond the preview
Go deeper on NL-OMON60384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60384.